EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study

Seyit Murat Bayram, Hüseyin Demirci, Enes Üçgül, Şule Canlar, Murat Cinel, Burak Menekşe, İlknur Alkan Kuşabbi, Erman Çakal

BMC Endocrine Disorders · 2026

DOI: 10.1186/s12902-026-02483-9 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift BMC Endocrine Disorders, 2026. Verfasst von Seyit Murat Bayram und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye. seyitmurat.bayram@saglik.gov.tr. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Thyrotropin, Inflammation. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim This retrospective study examined whether long-term SGLT-2i use is associated with differences in thyroid-stimulating hormone (TSH) and the systemic immune-inflammation index (SII) in patients with type 2 diabetes mellitus (T2DM) without known thyroid disease. The neutrophil-to-lymphocyte ratio (NLR), renal function (eGFR), diabetes duration, and metformin use were also evaluated as potential covariates.

Methods

This was a single-center, retrospective observational study. Adults with T2DM who had used empagliflozin or dapagliflozin for at least six months were compared with an age- and sex-matched control group of patients with T2DM not using SGLT-2i, drawn from the same outpatient clinics. Key exclusion criteria included known thyroid disease, known positivity for thyroid autoantibodies, active inflammatory or autoimmune processes, advanced organ failure, and immunomodulatory treatment. TSH, SII, and NLR were measured. Statistical analyses included intergroup comparisons, correlation, multivariate linear regression, post-hoc power calculation, and multicollinearity diagnostics (variance inflation factor, VIF).

Results

The study included 330 patients across the empagliflozin ( n = 139), dapagliflozin ( n = 85), and control ( n = 106) groups. Median TSH (1.6, 1.8, and 1.9 µIU/mL; p = 0.338) and SII (481, 531, and 468.5; p = 0.509) did not differ significantly between groups. SII and NLR were significantly correlated ( r = 0.467, p < 0.001). In multivariate regression, female sex (B = 0.161, p = 0.015) and eGFR (B=–0.0043, p = 0.037) were independent predictors of log-transformed TSH; SGLT-2i use, SII, NLR, age, metformin use, and diabetes duration were not. The study had 80% power to detect a Cohen’s f of 0.17 or greater; observed effect sizes were substantially below this threshold (f = 0.02 for TSH, f ≈ 0.00 for SII).

Conclusion

Long-term SGLT-2i use was not associated with significant changes in TSH or SII in patients with T2DM without known thyroid disease, and the achieved effect sizes suggest that any true effect, if present, is likely small. Renal function emerged as an independent correlate of TSH, suggesting that the relationship between the hypothalamic-pituitary-thyroid axis and renal physiology merits further attention in this population, independent of SGLT-2i exposure. Prospective, multicenter studies incorporating free thyroxine and triiodothyronine measurements are warranted to further clarify these relationships. Clinical trial number This study is retrospective and does not involve a clinical trial registration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsThyrotropinInflammationBiomarkersHumansFemaleRetrospective StudiesMaleMiddle AgedGlucosidesBenzhydryl CompoundsPrognosisAgedNeutrophilsCase-Control StudiesFollow-Up StudiesLymphocytes

Stichwörter der Autor:innen

DapagliflozinEmpagliflozinGlomerular filtration rateNeutrophil-lymphocyte ratioSodium-glucose transporter 2 inhibitorsSystemic immune-inflammation indexThyrotropinType 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucosidesThyrotropinBenzhydryl CompoundsdapagliflozinempagliflozinBiomarkers

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye. seyitmurat.bayram@saglik.gov.tr.
  • Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye.
  • Department of Medical Biochemistry, Ankara Etlik City Hospital, Ankara, Türkiye.

Zitieren

APA

Bayram, S. M., Demirci, H., Üçgül, E., Canlar, Ş., Cinel, M., Menekşe, B., Kuşabbi, İ. A., & Çakal, E. (2026). Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02483-9

Vancouver

Bayram SM, Demirci H, Üçgül E, Canlar Ş, Cinel M, Menekşe B, et al. Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study. BMC Endocrine Disorders. 2026. doi:10.1186/s12902-026-02483-9

BibTeX
@article{Bayram2026,
  author = {Bayram, Seyit Murat and Demirci, Hüseyin and Üçgül, Enes and Canlar, Şule and Cinel, Murat and Menekşe, Burak and Kuşabbi, İlknur Alkan and Çakal, Erman},
  title = {Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study},
  journal = {BMC Endocrine Disorders},
  year = {2026},
  doi = {10.1186/s12902-026-02483-9}
}
Kostenlos starten →